
    
      This is a multi-center, prospective, observational, US-based drug study. All consecutive
      Mycosis Fungoides Cutaneous T-cell Lymphoma (MF-CTCL) patients being treated with Valchlor
      will be invited to enroll in this study.Patients will undergo clinical assessments and
      receive standard medical care, as determined by the patients' physician, in the real world
      setting. With the exception of protocol-required patient completed questionnaires for
      symptoms and QOL, there are no specific or mandated clinical assessments to be performed.
      Patients will be followed prospectively for a maximum of 2 years
    
  